Latest Premier Biomedical (BIEI) Headlines
Premier Biomedical to Present Positive Pre-Clinical Breast Cancer Study at American Association for Cancer Research Annual Meeting
Marketwire - Wed Feb 26, 7:15AM CST
Premier Biomedical, Inc. (OTCQB: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease and traumatic brain injury, announced today that Premier Biomedical will present significantly positive results from duplicated testing on mice at the American Association for Cancer Research annual meeting in San Diego, California on April 5-9, 2014. The results demonstrated statistically significant improvements in survival and a prevention of breast cancer in mice treated with Premier Biomedical's anti-breast cancer treatment compared to both chemotherapy and a non-treated control group.
Premier Biomedical Met With NFL and NCAA Representatives During Super Bowl Week at Coalition for Concussion Treatment Summit at the United Nations
Marketwire - Thu Feb 13, 7:15AM CST
Premier Biomedical, Inc. (http://www.premierbiomedical.com/) (OTCQB: BIEI) today released the following statement regarding their participation in the Coalition for Concussion Treatment (#C4CT) Summit established by Brewer Sports International (http://www.brewersports.com/) (BSI) during Super Bowl Week at the United Nations Headquarters in New York City. The conference followed the announcement that Brewer Sports International and Premier Biomedical have entered into a long-term strategic partnership agreement to continue to explore innovative treatment methods for Traumatic Brain Injury (TBI) and other neurological diseases.
CEO CFO Magazine Interviews Premier Biomedical's CEO Hartman; Second Time in 16 Months
Marketwire - Tue Feb 11, 7:15AM CST
Premier Biomedical, Inc. (OTCQB: BIEI) (OTCBB: BIEI) today announced that President and Chief Executive Officer, William A. Hartman, was recently interviewed for a second time in 16 months by CEO/CFO Magazine, an independent investment publication which conducts interviews with company CEOs. The latest William Hartman interview appears in the publication's Biotechnology and Pharmaceuticals Report available by calling (570) 851-1745 or via CEO/CFO Magazine Online (http://www.ceocfointerviews.com). (The original interview was in the October, 2012 edition.)
Premier Biomedical Advances Vs Head Trauma
Marketwire - Wed Jan 22, 7:02AM CST
Premier Biomedical, Inc. (OTCQB: BIEI) today released the following statement regarding advances in the treatment of Head Trauma. There has been considerable news lately related to professional sports and the incidence rate of head trauma, also referred to as Traumatic Brain Injury, and its lasting effects on clinical depression, suicide/violence ideation, PTSD and longer term, persistent neurological diseases such as Parkinson's Disease, Alzheimer's Disease, and Amyotrophic Lateral Sclerosis (ALS). The scope of the problem is revealed by lesser known statistics published by the Veterans Administration, indicating suicide rates among active-duty personnel are almost one per day. If we include veterans, the number of suicides jumps to almost ONE PER HOUR. This is a huge morale problem and one that demands our collective utmost attention.
MTS Systems and Chery Automobile Company Celebrate The Opening of Their Joint Vehicle System Engineering Laboratory In China
PR Newswire - Thu Jan 09, 5:40PM CST
MTS Systems Corporation (NASDAQ: MTSC), a leading global supplier of high-performance test systems and position sensors, today announced the grand opening of a vehicle system engineering laboratory in collaboration with Chery Automobile Co. Ltd. in Wuhu, China. The first MTS joint laboratory with a domestic Chinese automotive OEM, the Chery-MTS lab is a center for system and full-vehicle testing applications, as well as the development of new testing technologies.
Premier Biomedical Inc enters into USD5m equity funding with Kodiak Capital Group LLC
M2 - Tue Dec 17, 5:35AM CST
Biopharmaceutical company Premier Biomedical Inc (OTCBB:BIEI) revealed on Monday the execution of a USD5m common stock purchase agreement with Kodiak Capital Group LLC.
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
Marketwire - Mon Dec 16, 7:01AM CST
Premier Biomedical, Inc. (OTCBB: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as novel therapies for Alzheimer's disease and traumatic brain injury, announced that it has entered into a $5 million common stock purchase agreement with Kodiak Capital Group, LLC, a Newport Beach-based institutional investor. The company has agreed to file a registration statement with the U.S. Securities & Exchange Commission ("SEC") covering the shares that may be issued to Kodiak under the terms of the common stock purchase agreement. After the SEC has declared the registration statement related to the transaction effective, the company has the right at its sole discretion over a period of one year to sell up to $5 million of common stock under the terms set forth in the agreement.
Confirmatory Testing Affirms Prevention of Metastasis in Premier Biomedical Candidate Therapy for Breast Cancer
Marketwire - Thu Dec 05, 7:01AM CST
Premier Biomedical, Inc. (OTCQB: BIEI), in concert with The University of Texas at El Paso, has conducted a confirmatory study supporting the ability of its breast cancer therapy to outperform chemotherapy in mice -- those on this regimen had a distinctively higher survival rate, smaller tumor volume, and maintained weight, as opposed to losing body mass as was demonstrated by control subjects on standard chemotherapy.
Premier Biomedical, Inc. Expands Intellectual Property for Multiple Sclerosis
ACCESSWIRE - Thu Aug 22, 7:05AM CDT
El Paso, TX, August 22, 2013 - (Accesswie) - Premier Biomedical, Inc. (OTCQB: BIEI) (http://www.premierbiomedical.com/), today announced that the company is pursuing an international patent application for its core technology to treat multiple sclerosis (MS). Development of Premier's therapy, which is functionally similar to its technology for traumatic brain injury, cancer, and Alzheimer's disease, is anticipated to occur through the company's existing research channels. Premier has already registered its technology behind multiple provisional patents in the United States and a Europe National Patent in the areas of cancer, blood sepsis, and Alzheimer's disease. In total, the company holds nine provisional patent applications and six international patent applications.
US Army Selects Premier Biomedical, Inc. for Cure for Traumatic Brain Injury, Clinical Depression, and Suicide Ideation; Joint Press Conference with Video
ACCESSWIRE - Thu Aug 01, 7:05AM CDT
El Paso, TX, August 1, 2013 - Premier Biomedical, Inc. (OTCQB: BIEI)
Premier Biomedical Recaps Press Conference on Cooperative Research and Development with U.S. Army William Beaumont Medical Center
ACCESSWIRE - Wed Jul 17, 7:06AM CDT
El Paso, TX, July 16, 2013 - (eTeligis via Accesswie) --- Premier Biomedical, Inc. (OTCQB: BIEI), (http://www.premierbiomedical.com/) today provided a recap of a special press conference held on Wednesday, July 10th in El Paso, Texas to provide the public with details on its Cooperative Research and Development Agreement (CRADA) recently established with the Department of Defense via the William Beaumont Army Medical Center (WBAMC) at Fort Bliss. Under terms of the CRADA, WBAMC will utilize Premier Biomedical's scientific technology for advanced and clinical research on medical treatments targeting the prevention of suicidal ideation and clinical depression as well as therapies for traumatic brain injury induced maladies including posttraumatic stress disorder (PTSD) and suicide.
Cancer Therapy by Premier Biomedical Outperforms Chemotherapy in Laboratory Study
ACCESSWIRE - Tue Jun 25, 7:01AM CDT
Premier Biomedical, Inc. (OTCBB: BIEI), has released the results of a completed phase-1 mouse testing of its breast cancer therapy. Premier Biomedical's cancer treatment methodology outperformed chemotherapy, the standard treatment option demonstrating a much lower mortality rate, smaller tumor volume, and increased subject weight gain recorded nineteen days after first treatment.
Premier Biomedical Inc enters into CRADA with William Beaumont Army Medical Center for traumatic brain injury & suicidal ideation/prevention
M2 - Wed Jun 12, 4:59AM CDT
Medical research company Premier Biomedical Inc (OTC BB:BIEI) reported on Tuesday the execution of a Cooperative Research and Development Agreement (CRADA) with William Beaumont Army Medical Center (WBAMC) located at Fort Bliss, in El Paso, Texas.
Premier Biomedical, Inc. Announces Next Phase of Laboratory Testing of its Anti-Cancer Therapy
PR Newswire - Thu Mar 28, 7:00AM CDT
Premier Biomedical, Inc. (OTC-BB: BIEI) (http://www.premierbiomedical.com/) today announced that it has advanced its pre-clinical testing of its extracorporeal-treatment methodology for use against cancer from test tubes to mice. These tests are being conducted by academic researchers at The University of Texas at El Paso (UTEP) under direction of Dr. Mitchell S. Felder of Premier Biomedical (PBI).
Premier Biomedical, Inc. Announces Potential Therapy for Retinitis Pigmentosa
PR Newswire - Thu Feb 21, 7:00AM CST
Premier Biomedical, Inc. (OTC-BB: BIEI) today announced that it has acquired exclusive rights to a provisional patent application against Retinitis Pigmentosa. This exclusive intellectual property right, a result of Premier's long-standing licensing agreements, proposes a novel method for treating the degenerative eye disease via the targeted removal of specified target antigens. This is the latest of many proposed applications of Premier Biomedical, Inc.'s Felder Doctrine(TM).
Premier Biomedical Announces Therapeutic Advance in the Treatment and Prevention of Suicide and Depression
PR Newswire - Tue Dec 18, 7:00AM CST
Premier Biomedical, Inc. (OTC-BB: BIEI) today announced a major achievement in its effort to develop a therapy for suicidal ideation and clinical depression. Premier Biomedical, Inc., which to date has achieved promising and innovative successes against cancer without application of any medication, was successful in removing the majority of target antigens associated with these two depressive disorder diseases from a heterogeneous mixture in the laboratory.
Premier Biomedical to Present Positive Pre-Clinical Breast Cancer Study at American Association for Cancer Research Annual Meeting
Marketwire - Wed Feb 26, 7:15AM CST
Premier Biomedical, Inc. (OTCQB: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease and traumatic brain injury, announced today that Premier Biomedical will present significantly positive results from duplicated testing on mice at the American Association for Cancer Research annual meeting in San Diego, California on April 5-9, 2014. The results demonstrated statistically significant improvements in survival and a prevention of breast cancer in mice treated with Premier Biomedical's anti-breast cancer treatment compared to both chemotherapy and a non-treated control group.
Premier Biomedical Met With NFL and NCAA Representatives During Super Bowl Week at Coalition for Concussion Treatment Summit at the United Nations
Marketwire - Thu Feb 13, 7:15AM CST
Premier Biomedical, Inc. (http://www.premierbiomedical.com/) (OTCQB: BIEI) today released the following statement regarding their participation in the Coalition for Concussion Treatment (#C4CT) Summit established by Brewer Sports International (http://www.brewersports.com/) (BSI) during Super Bowl Week at the United Nations Headquarters in New York City. The conference followed the announcement that Brewer Sports International and Premier Biomedical have entered into a long-term strategic partnership agreement to continue to explore innovative treatment methods for Traumatic Brain Injury (TBI) and other neurological diseases.
CEO CFO Magazine Interviews Premier Biomedical's CEO Hartman; Second Time in 16 Months
Marketwire - Tue Feb 11, 7:15AM CST
Premier Biomedical, Inc. (OTCQB: BIEI) (OTCBB: BIEI) today announced that President and Chief Executive Officer, William A. Hartman, was recently interviewed for a second time in 16 months by CEO/CFO Magazine, an independent investment publication which conducts interviews with company CEOs. The latest William Hartman interview appears in the publication's Biotechnology and Pharmaceuticals Report available by calling (570) 851-1745 or via CEO/CFO Magazine Online (http://www.ceocfointerviews.com). (The original interview was in the October, 2012 edition.)
Premier Biomedical Advances Vs Head Trauma
Marketwire - Wed Jan 22, 7:02AM CST
Premier Biomedical, Inc. (OTCQB: BIEI) today released the following statement regarding advances in the treatment of Head Trauma. There has been considerable news lately related to professional sports and the incidence rate of head trauma, also referred to as Traumatic Brain Injury, and its lasting effects on clinical depression, suicide/violence ideation, PTSD and longer term, persistent neurological diseases such as Parkinson's Disease, Alzheimer's Disease, and Amyotrophic Lateral Sclerosis (ALS). The scope of the problem is revealed by lesser known statistics published by the Veterans Administration, indicating suicide rates among active-duty personnel are almost one per day. If we include veterans, the number of suicides jumps to almost ONE PER HOUR. This is a huge morale problem and one that demands our collective utmost attention.
MTS Systems and Chery Automobile Company Celebrate The Opening of Their Joint Vehicle System Engineering Laboratory In China
PR Newswire - Thu Jan 09, 5:40PM CST
MTS Systems Corporation (NASDAQ: MTSC), a leading global supplier of high-performance test systems and position sensors, today announced the grand opening of a vehicle system engineering laboratory in collaboration with Chery Automobile Co. Ltd. in Wuhu, China. The first MTS joint laboratory with a domestic Chinese automotive OEM, the Chery-MTS lab is a center for system and full-vehicle testing applications, as well as the development of new testing technologies.
Premier Biomedical Inc enters into USD5m equity funding with Kodiak Capital Group LLC
M2 - Tue Dec 17, 5:35AM CST
Biopharmaceutical company Premier Biomedical Inc (OTCBB:BIEI) revealed on Monday the execution of a USD5m common stock purchase agreement with Kodiak Capital Group LLC.
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
Marketwire - Mon Dec 16, 7:01AM CST
Premier Biomedical, Inc. (OTCBB: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as novel therapies for Alzheimer's disease and traumatic brain injury, announced that it has entered into a $5 million common stock purchase agreement with Kodiak Capital Group, LLC, a Newport Beach-based institutional investor. The company has agreed to file a registration statement with the U.S. Securities & Exchange Commission ("SEC") covering the shares that may be issued to Kodiak under the terms of the common stock purchase agreement. After the SEC has declared the registration statement related to the transaction effective, the company has the right at its sole discretion over a period of one year to sell up to $5 million of common stock under the terms set forth in the agreement.
Confirmatory Testing Affirms Prevention of Metastasis in Premier Biomedical Candidate Therapy for Breast Cancer
Marketwire - Thu Dec 05, 7:01AM CST
Premier Biomedical, Inc. (OTCQB: BIEI), in concert with The University of Texas at El Paso, has conducted a confirmatory study supporting the ability of its breast cancer therapy to outperform chemotherapy in mice -- those on this regimen had a distinctively higher survival rate, smaller tumor volume, and maintained weight, as opposed to losing body mass as was demonstrated by control subjects on standard chemotherapy.
Premier Biomedical, Inc. Expands Intellectual Property for Multiple Sclerosis
ACCESSWIRE - Thu Aug 22, 7:05AM CDT
El Paso, TX, August 22, 2013 - (Accesswie) - Premier Biomedical, Inc. (OTCQB: BIEI) (http://www.premierbiomedical.com/), today announced that the company is pursuing an international patent application for its core technology to treat multiple sclerosis (MS). Development of Premier's therapy, which is functionally similar to its technology for traumatic brain injury, cancer, and Alzheimer's disease, is anticipated to occur through the company's existing research channels. Premier has already registered its technology behind multiple provisional patents in the United States and a Europe National Patent in the areas of cancer, blood sepsis, and Alzheimer's disease. In total, the company holds nine provisional patent applications and six international patent applications.
US Army Selects Premier Biomedical, Inc. for Cure for Traumatic Brain Injury, Clinical Depression, and Suicide Ideation; Joint Press Conference with Video
ACCESSWIRE - Thu Aug 01, 7:05AM CDT
El Paso, TX, August 1, 2013 - Premier Biomedical, Inc. (OTCQB: BIEI)
Premier Biomedical Recaps Press Conference on Cooperative Research and Development with U.S. Army William Beaumont Medical Center
ACCESSWIRE - Wed Jul 17, 7:06AM CDT
El Paso, TX, July 16, 2013 - (eTeligis via Accesswie) --- Premier Biomedical, Inc. (OTCQB: BIEI), (http://www.premierbiomedical.com/) today provided a recap of a special press conference held on Wednesday, July 10th in El Paso, Texas to provide the public with details on its Cooperative Research and Development Agreement (CRADA) recently established with the Department of Defense via the William Beaumont Army Medical Center (WBAMC) at Fort Bliss. Under terms of the CRADA, WBAMC will utilize Premier Biomedical's scientific technology for advanced and clinical research on medical treatments targeting the prevention of suicidal ideation and clinical depression as well as therapies for traumatic brain injury induced maladies including posttraumatic stress disorder (PTSD) and suicide.
Cancer Therapy by Premier Biomedical Outperforms Chemotherapy in Laboratory Study
ACCESSWIRE - Tue Jun 25, 7:01AM CDT
Premier Biomedical, Inc. (OTCBB: BIEI), has released the results of a completed phase-1 mouse testing of its breast cancer therapy. Premier Biomedical's cancer treatment methodology outperformed chemotherapy, the standard treatment option demonstrating a much lower mortality rate, smaller tumor volume, and increased subject weight gain recorded nineteen days after first treatment.
Premier Biomedical Inc enters into CRADA with William Beaumont Army Medical Center for traumatic brain injury & suicidal ideation/prevention
M2 - Wed Jun 12, 4:59AM CDT
Medical research company Premier Biomedical Inc (OTC BB:BIEI) reported on Tuesday the execution of a Cooperative Research and Development Agreement (CRADA) with William Beaumont Army Medical Center (WBAMC) located at Fort Bliss, in El Paso, Texas.
Premier Biomedical, Inc. Announces Next Phase of Laboratory Testing of its Anti-Cancer Therapy
PR Newswire - Thu Mar 28, 7:00AM CDT
Premier Biomedical, Inc. (OTC-BB: BIEI) (http://www.premierbiomedical.com/) today announced that it has advanced its pre-clinical testing of its extracorporeal-treatment methodology for use against cancer from test tubes to mice. These tests are being conducted by academic researchers at The University of Texas at El Paso (UTEP) under direction of Dr. Mitchell S. Felder of Premier Biomedical (PBI).
Premier Biomedical, Inc. Announces Potential Therapy for Retinitis Pigmentosa
PR Newswire - Thu Feb 21, 7:00AM CST
Premier Biomedical, Inc. (OTC-BB: BIEI) today announced that it has acquired exclusive rights to a provisional patent application against Retinitis Pigmentosa. This exclusive intellectual property right, a result of Premier's long-standing licensing agreements, proposes a novel method for treating the degenerative eye disease via the targeted removal of specified target antigens. This is the latest of many proposed applications of Premier Biomedical, Inc.'s Felder Doctrine(TM).
Premier Biomedical Announces Therapeutic Advance in the Treatment and Prevention of Suicide and Depression
PR Newswire - Tue Dec 18, 7:00AM CST
Premier Biomedical, Inc. (OTC-BB: BIEI) today announced a major achievement in its effort to develop a therapy for suicidal ideation and clinical depression. Premier Biomedical, Inc., which to date has achieved promising and innovative successes against cancer without application of any medication, was successful in removing the majority of target antigens associated with these two depressive disorder diseases from a heterogeneous mixture in the laboratory.
